Tobacco Cessation Counseling for Lung Cancers

Phase-Based Progress Estimates
Lung Cancers+2 More
Tobacco Cessation Counseling - Other
All Sexes
What conditions do you have?

Study Summary

This trial studies whether a centralized care strategy, where smokers eligible for lung cancer screening are referred to a dedicated tobacco treatment program, works better in helping people quit smoking and make informed decisions about lung cancer screening compared to usual care.

Eligible Conditions
  • Lung Cancers
  • Smoking

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Lung Cancers

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Up to 12 weeks

Up to 12 weeks
Acceptability, appropriateness, and feasibility of the intervention measure (Weiner et al).
Costs of implementing any smoking cessation plus shared decision making intervention
EuroQoL-5 dimensions
Fidelity checklist (11 items)
Lung Cancer Screening 12 items version
Number of patients who received smoking cessation counseling and shared decision making over the number of patients consented to participate in the study
Smoking abstinence Questionnairre

Trial Safety

Safety Progress

1 of 3

Other trials for Lung Cancers

Trial Design

2 Treatment Groups

Group II (usual care)
1 of 2
Group I (centralized care strategy)
1 of 2
Active Control
Experimental Treatment

520 Total Participants · 2 Treatment Groups

Primary Treatment: Tobacco Cessation Counseling · No Placebo Group · Phase < 1

Group I (centralized care strategy)Experimental Group · 4 Interventions: Tobacco Cessation Counseling, Quality-of-Life Assessment, Nicotine Patch, Questionnaire Administration · Intervention Types: Other, Other, Drug, Other
Group II (usual care)ActiveComparator Group · 3 Interventions: Quality-of-Life Assessment, Best Practice, Questionnaire Administration · Intervention Types: Other, Other, Other
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 weeks

Who is running the clinical trial?

Cancer Prevention Research Institute of TexasOTHER
41 Previous Clinical Trials
78,391 Total Patients Enrolled
National Cancer Institute (NCI)NIH
12,989 Previous Clinical Trials
41,298,538 Total Patients Enrolled
547 Trials studying Lung Cancers
329,710 Patients Enrolled for Lung Cancers
M.D. Anderson Cancer CenterLead Sponsor
2,779 Previous Clinical Trials
1,784,499 Total Patients Enrolled
88 Trials studying Lung Cancers
23,540 Patients Enrolled for Lung Cancers
Robert J VolkPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
880 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.